Lexeo Therapeutics, a New York City-based genetic medicine company, focuses on therapies for hereditary and acquired diseases and recently went public on November 3, 2023. Its pipeline includes cardiovascular candidates LX2006 and LX2020, both undergoing clinical evaluation.